Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
Mr. Humer joins Foghorn with over 14 years of diversified financial strategy and business development experience in the life science industry and more than 20 years of experience in the financial industry.
- Mr. Humer joins Foghorn with over 14 years of diversified financial strategy and business development experience in the life science industry and more than 20 years of experience in the financial industry.
- “Kristian is a seasoned executive with a breadth of capital markets expertise, established relationships within the financial community, and a deep understanding of the industry landscape,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn.
- Kristian Humer, Chief Financial Officer of Foghorn, added, “Foghorn is a leader in chromatin biology and at the forefront of drug discovery in this novel – and significant – area.
- Mr. Humer is a member of the board of Sensei Biotherapeutics, a public biotechnology company.